Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis

Taro Kishi, Toshikazu Ikuta, Yuki Matsuda, Nakao Iwata

研究成果: Article

抄録

Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95% CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.

元の言語English
ページ(範囲)256-259
ページ数4
ジャーナルNeuropsychopharmacology reports
39
発行部数3
DOI
出版物ステータスPublished - 01-09-2019

Fingerprint

olanzapine
Bayes Theorem
Bipolar Disorder
Odds Ratio
Depression
Quetiapine Fumarate
Incidence
Prolactin
HDL Cholesterol

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

@article{9d2777422ddf46589e250213a227042d,
title = "Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis",
abstract = "Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-{\AA}sberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95{\%} credible interval (95{\%} CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95{\%} CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95{\%} CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95{\%} CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95{\%} CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.",
author = "Taro Kishi and Toshikazu Ikuta and Yuki Matsuda and Nakao Iwata",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/npr2.12070",
language = "English",
volume = "39",
pages = "256--259",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression : A Bayesian analysis. / Kishi, Taro; Ikuta, Toshikazu; Matsuda, Yuki; Iwata, Nakao.

:: Neuropsychopharmacology reports, 巻 39, 番号 3, 01.09.2019, p. 256-259.

研究成果: Article

TY - JOUR

T1 - Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression

T2 - A Bayesian analysis

AU - Kishi, Taro

AU - Ikuta, Toshikazu

AU - Matsuda, Yuki

AU - Iwata, Nakao

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95% CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.

AB - Objective: It is unknown whether there are differences in efficacy and safety between quetiapine extended-release, 300 mg/d (QUEXR300), and olanzapine, 5-20 mg/d (OLA), for Japanese patients with bipolar depression. Methods: We conducted a Bayesian analysis of data from phase 3 studies in Japan of QUEXR300 and OLA. Outcomes were remission rate (primary), response rate, improvement on the Montgomery-Åsberg Depression Rating Scale and 17-item Hamilton Depression Rating Scale scores, discontinuation rate, and incidence of individual adverse events. We calculated the standardized mean difference (SMD) and the risk ratio (RR) and 95% credible interval (95% CrI) for continuous and dichotomous data, respectively. Results: There were no significant differences between QUEXR300 and OLA for any of the efficacy outcomes. QUEXR300 was associated with a higher incidence of somnolence than OLA (RR = 5.517; 95% CrI = 1.563, 19.787), while OLA was associated with greater increase body weight (SMD = −0.488; 95% CrI = −0.881, −0.089) and blood prolactin levels (SMD = −0.642; 95% CrI = −1.073, −0.213) than QUEXR300, and a greater decrease in high-density lipoprotein cholesterol levels (SMD = −0.408; 95% CrI = −0.785, −0.030) than QUEXR300. Conclusion: Although the two drugs’ efficacy did not differ, OLA increased the risk of metabolic syndrome and QUEXR300 the risk of somnolence. A large scale, long-term, head-to-head comparison study of QUEXR300 vs OLA for Japanese patients with bipolar depression is needed to confirm the results of the current study.

UR - http://www.scopus.com/inward/record.url?scp=85071784839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071784839&partnerID=8YFLogxK

U2 - 10.1002/npr2.12070

DO - 10.1002/npr2.12070

M3 - Article

C2 - 31283865

AN - SCOPUS:85071784839

VL - 39

SP - 256

EP - 259

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

IS - 3

ER -